The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer
Cancer · 2024
DOI: 10.1002/cncr.35215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Avery E Braun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Grading, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NIH HHS.
Abstract (Originalsprache)
Background
The challenge of distinguishing indolent from aggressive prostate cancer (PCa) complicates decision‐making for men considering active surveillance (AS). Genomic classifiers (GCs) may improve risk stratification by predicting end points such as upgrading or upstaging (UG/US). The aim of this study was to assess the impact of GCs on UG/US risk prediction in a clinicopathologic model.
Methods
Participants had favorable‐risk PCa (cT1‐2, prostate‐specific antigen [PSA] ≤15 ng/mL, and Gleason grade group 1 [GG1]/low‐volume GG2). A prediction model was developed for 864 men at the University of California, San Francisco, with standard clinical variables (cohort 1), and the model was validated for 2267 participants from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry (cohort 2). Logistic regression was used to compute the area under the receiver operating characteristic curve (AUC) to develop a prediction model for UG/US at prostatectomy. A GC (Oncotype Dx Genomic Prostate Score [GPS] or Prolaris) was then assessed to improve risk prediction.
Results
The prediction model included biopsy GG1 versus GG2 (odds ratio [OR], 5.83; 95% confidence interval [CI], 3.73–9.10); PSA (OR, 1.10; 95% CI, 1.01–1.20; per 1 ng/mL), percent positive cores (OR, 1.01; 95% CI, 1.01–1.02; per 1%), prostate volume (OR, 0.98; 95% CI, 0.97–0.99; per mL), and age (OR, 1.05; 95% CI, 1.02–1.07; per year), with AUC 0.70 (cohort 1) and AUC 0.69 (cohort 2). GPS was associated with UG/US (OR, 1.03; 95% CI, 1.01–1.06; p < .01) and AUC 0.72, which indicates a comparable performance to the prediction model.
Conclusions
GCs did not substantially improve a clinical prediction model for UG/US, a short‐term and imperfect surrogate for clinically relevant disease outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of California, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
- Department of Surgery, University of California, San Francisco, California, USA.
- Department of Pathology, University of California, San Francisco, California, USA.
ORCID-Profile: Avery E Braun, Stacey A Kenfield
Förderung
- NIH HHS
Zitieren
APA
Braun, A. E., Chan, J. M., Neuhaus, J., Cowan, J. E., Kenfield, S. A., Van Blarigan, E. L., Tenggara, I., Broering, J. M., Simko, J. P., Carroll, P. R., & Cooperberg, M. R. (2024). The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer. Cancer. https://doi.org/10.1002/cncr.35215
Vancouver
Braun AE, Chan JM, Neuhaus J, Cowan JE, Kenfield SA, Van Blarigan EL, et al. The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer. Cancer. 2024. doi:10.1002/cncr.35215
BibTeX
@article{Braun2024,
author = {Braun, Avery E and Chan, June M and Neuhaus, John and Cowan, Janet E and Kenfield, Stacey A and Van Blarigan, Erin L and Tenggara, Imelda and Broering, Jeanette M and Simko, Jeffry P and Carroll, Peter R and Cooperberg, Matthew R},
title = {The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35215}
}
EUVIMED